Eupraxia Pharmaceuticals
  • Home
  • Who We Are
    • What We Believe
    • Board of Directors
    • Management Team
  • Pipeline
    • Arthritis
    • Chronic Pain
    • Early Stage Research
    • Veterinary Health
  • Partnering
  • Careers
  • Contact Us
Select Page

Eupraxia announces first patient dosed in phase I clinical trial of EP-104IAR to treat osteoarthritis-related pain

May 17, 2016 | Arthritis Program, Phase I, Press Release, Research

VICTORIA, BC – Eupraxia, an emerging pharmaceutical company focused on optimizing drug delivery, announced today the initiation of STEP UP – a phase I study of its lead investigational product (EP-104IAR), for the treatment of pain associated with osteoarthritis (OA)...

Recent Posts

  • Eupraxia will be at #BIOEurope 2018
  • Eupraxia team presented in PAINWeek 2018 – Las Vegas
  • Meet Us at BioConvention 2018 in Boston
  • Meet us at the 6th Annual Drug Repositioning, Repurposing and Rescue Conference in Chicago 2017
  • Meet us at BIOConvention 2017 in San Diego
  • Home
  • Privacy Policy
  • Terms of Use

Designed by Elegant Themes | Powered by WordPress

Copyright © 2021 EupraxiaPharma.com | Design Powered by Divi Theme